Your browser doesn't support javascript.
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
Gabitzsch, Elizabeth; Safrit, Jeffrey T; Verma, Mohit; Rice, Adrian; Sieling, Peter; Zakin, Lise; Shin, Annie; Morimoto, Brett; Adisetiyo, Helty; Wong, Raymond; Bezawada, Ashish; Dinkins, Kyle; Balint, Joseph; Peykov, Victor; Garban, Hermes; Liu, Philip; Bacon, Andrew; Bone, Pete; Drew, Jeff; Sanford, Daniel C; Spilman, Patricia; Sender, Lennie; Rabizadeh, Shahrooz; Niazi, Kayvan; Soon-Shiong, Patrick.
  • Gabitzsch E; ImmunityBio, Inc., Culver City, CA, United States.
  • Safrit JT; ImmunityBio, Inc., Culver City, CA, United States.
  • Verma M; ImmunityBio, Inc., Culver City, CA, United States.
  • Rice A; ImmunityBio, Inc., Culver City, CA, United States.
  • Sieling P; ImmunityBio, Inc., Culver City, CA, United States.
  • Zakin L; ImmunityBio, Inc., Culver City, CA, United States.
  • Shin A; ImmunityBio, Inc., Culver City, CA, United States.
  • Morimoto B; ImmunityBio, Inc., Culver City, CA, United States.
  • Adisetiyo H; ImmunityBio, Inc., Culver City, CA, United States.
  • Wong R; ImmunityBio, Inc., Culver City, CA, United States.
  • Bezawada A; ImmunityBio, Inc., Culver City, CA, United States.
  • Dinkins K; ImmunityBio, Inc., Culver City, CA, United States.
  • Balint J; ImmunityBio, Inc., Culver City, CA, United States.
  • Peykov V; ImmunityBio, Inc., Culver City, CA, United States.
  • Garban H; ImmunityBio, Inc., Culver City, CA, United States.
  • Liu P; ImmunityBio, Inc., Culver City, CA, United States.
  • Bacon A; IosBio, Burgess Hill, United Kingdom.
  • Bone P; IosBio, Burgess Hill, United Kingdom.
  • Drew J; IosBio, Burgess Hill, United Kingdom.
  • Sanford DC; Battelle Biomedical Research Center, Columbus, OH, United States.
  • Spilman P; ImmunityBio, Inc., Culver City, CA, United States.
  • Sender L; NantKwest, Inc., Culver City, CA, United States.
  • Rabizadeh S; ImmunityBio, Inc., Culver City, CA, United States.
  • Niazi K; ImmunityBio, Inc., Culver City, CA, United States.
  • Soon-Shiong P; ImmunityBio, Inc., Culver City, CA, United States.
Front Immunol ; 12: 729837, 2021.
Article in English | MEDLINE | ID: covidwho-1450810
ABSTRACT
We have developed a dual-antigen COVID-19 vaccine incorporating genes for a modified SARS-CoV-2 spike protein (S-Fusion) and the viral nucleocapsid (N) protein with an Enhanced T-cell Stimulation Domain (N-ETSD) to increase the potential for MHC class II responses. The vaccine antigens are delivered by a human adenovirus serotype 5 platform, hAd5 [E1-, E2b-, E3-], previously demonstrated to be effective in the presence of Ad immunity. Vaccination of rhesus macaques with the hAd5 S-Fusion + N-ETSD vaccine by subcutaneous prime injection followed by two oral boosts elicited neutralizing anti-S IgG and T helper cell 1-biased T-cell responses to both S and N that protected the upper and lower respiratory tracts from high titer (1 x 106 TCID50) SARS-CoV-2 challenge. Notably, viral replication was inhibited within 24 hours of challenge in both lung and nasal passages, becoming undetectable within 7 days post-challenge.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Limits: Animals Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.729837

Full text: Available Collection: International databases Database: MEDLINE Main subject: Spike Glycoprotein, Coronavirus / Coronavirus Nucleocapsid Proteins / COVID-19 Vaccines / SARS-CoV-2 / COVID-19 Limits: Animals Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.729837